Type II autoimmune hepatitis: the conundrum of cytochrome P450IID6

D. Vergani,G. Mieli-Vergani

DOI: https://doi.org/10.1111/j.1365-2249.1993.tb03406.x

1993-06-01

Abstract:Liver kidney microsome-1 (LKM-1) antibody defines a subtype of autoimmune hepatitis referred to as type II [1]. This type of autoimmune hepatitis preferentially affects children or young adults, mainly females, and runs a particularly severe clinical course, with frequent evolution to cirrhosis despite apparent response to immunosuppressive treatment. Although its onset is usually insidious, it can present with acute hepatic failure. Histological examination of the liver shows severe mononuclear inflammatory cell infiltration of the portal tracts, which extends into the parenchyma surrounding dying hepatocytes. A major target for the diagnostic LKM-1 antibody is the cytochrome P450IID6 [2-4], which metabolizes debrisoquin and several other drugs [2-5]. Autoimmune hepatitis type II, LKM-1 antibody and its targets have recently been the focus of a lively debate. The observation that short amino acid sequences are shared in common between cytochrome P450IID6 and hepatitis C virus (HCV) has led to the proposal that HCV triggers a crossreactive autoimmune response which could play an important role in the development of autoimmune hepatitis type II [6]. A link between HCV and LKM-1 reactivity is confirmed in this issue by Seelig et al. [7], who demonstrate the presence of HCV RNA in the serum of approximately half of the patients positive for LKM-1. The patients positive for both HCV and LKM-1, however, were mainly males and older than those positive for LKM-1 only, an intriguing observation which has been made previously [8-10]. Although Seelig et al. [7] found that virtually all LKM-1-positive sera reacted with recombinant P450IID6, other works indicate that the target of LKM-1 is different in autoimmune hepatitis type II and chronic HCV infection [ 10,11 ]. This suggests that, on the basis of the available data, it is unwise to draw conclusions on the role of HCV in triggering autoimmune hepatitis type II. An additional paper in this issue by Yamamoto et al. [12], which concentrates on the classical autoimmune hepatitis type II, addresses another hot question: does LKM-1 play a direct pathogenic role? For LKM-1 to be pathogenically relevant, its target, cytochrome P450IID6, should be easily accessible to the immune system on the outer aspect of the hepatocyte plasma membrane. Making use of a variety of refined techniques, these authors concluded that in aHlikelihood P450IID6 is not present on the cell surface of normal human hepatocytes. Recently, however, Loeper et al. [13], addressing the same question and using a variety of similarly refined techniques, concluded that Medicine